This program will provide an update of current standards of therapy for first- and second line treatment of extensive-stage small cell lung cancer (SCLC). Management of limited-stage disease will also be discussed. Indications for radiotherapy in the management of limited and extensive stage patients will be addressed. In addition, new directions in SCLC treatment, including immunotherapy and emerging targeted therapy approaches will be presented. Discussion will also focus on potential biomarkers to direct therapy in SCLC.
After viewing this webinar, attendees will:
- Recognize current treatment standards for limited and extensive stage SCLC;
- Identify new immunotherapy and targeted-therapy approaches; and
- Indicate ongoing and planned clinical trials that will impact patient care in the near future.
Suresh S. Ramalingam, MD
Professor of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute.
Charles Rudin, MD, PhD
Chief, Thoracic Oncology Service, Sylvia Hassenfeld Chair in Lung Cancer Research, Co-Director, Drukenmiller Center, for Lung Cancer Research, Professor of Medicine, WCMC, Memorial Sloan Kettering Cancer Center.
For any inquiries, please contact meetings@iaslc.org.
After viewing this webinar, attendees will:
- Recognize current treatment standards for limited and extensive stage SCLC;
- Identify new immunotherapy and targeted-therapy approaches; and
- Indicate ongoing and planned clinical trials that will impact patient care in the near future.
Suresh S. Ramalingam, MD
Professor of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute.
Charles Rudin, MD, PhD
Chief, Thoracic Oncology Service, Sylvia Hassenfeld Chair in Lung Cancer Research, Co-Director, Drukenmiller Center, for Lung Cancer Research, Professor of Medicine, WCMC, Memorial Sloan Kettering Cancer Center.
For any inquiries, please contact meetings@iaslc.org.